(Reuters) – Syneos Health Inc (SYNH.O), a U.S. contract research organization (CRO) that serves the pharmaceutical industry, is exploring a sale, people familiar with the matter said on Monday. A deal for Syneos would be the latest in string of…
Shionogi and Tetra expand partnership ahead of Alzheimer’s trial readout
Shionogi has expanded its partnership with its Alzheimer’s drug development partner Tetra Therapeutics, giving an option for a buyout of the US biotech ahead of a key trial milestone. The two companies will work together to develop and market BPN14770…
EyePoint Reports Long-Term Positive Results from Phase III Yutiq Trial
EyePoint Pharmaceuticals, based in Watertown, Massachusetts, announcedpositive topline 36-month follow-up data from the second Phase III trial of Yutiq (fluocinolone acetonide intravitreal implant) for treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. Yutiq was approved by…
Karyopharm’s Xpovio Hits the Mark in Phase III Multiple Myeloma Trial
Shares of Karyopharm Therapeutics soared Monday after the company posted positive Phase III results in multiple myeloma and announced it is planning a regulatory submission in the second quarter of this year for its combination of Xpovio, Velcade and Dexamethasone.…
Amicus Opens New Global Research and Gene Therapy Center of Excellence in Philadelphia
CRANBURY, N.J. and PHILADELPHIA, March 05, 2020 (GLOBE NEWSWIRE) — Amicus Therapeutics, Inc. (Nasdaq: FOLD) today announced the official opening of the company’s Global Research and Gene Therapy Center of Excellence in uCity Square in Philadelphia to advance its industry leading portfolio…
Novartis Teams Up with Startup Orionis to Tackle Elusive Drug Targets
Massachusetts-based Orionis Biosciences has flown under the radar since its founding in 2015, has leaped into the mainstream this morning with a major four-year drug discovery collaboration with Swiss pharma giant Novartis. The two companies forged a collaboration to discover…
Gilead Launches Two Phase III Trials of Remdesivir for COVID-19
Gilead Sciences, based in Foster City, California, announced it will launch two Phase III clinical trials of its investigational antiviral drug remdesivir in adults diagnosed with COVID-19, the disease caused by the novel coronavirus. The outbreak began in China in…
Allecra’s Exblifep Effective in Hospital-Based Urinary Tract Infections
Allecra Therapeutics, with locations in Saint-Louis, France and Weil, Am Rhein, Germany, indicated its Exblifep (cefepime-enmetazobactam) hit pre-specified primary endpoints in its Phase III ALLIUM clinical trial in complicated urinary tract infections (cUTI), including acute pyelonephritis (AP). It also demonstrated…
Chinese biotech censured for misleading coronavirus drug claims
China’s BrightGene Bio-Medical Technology has been censured by the Shanghai Stock Exchange for wrongly claiming it is able to manufacture Gilead’s experimental drug remdesivir – scientists’ best hope of a treatment for the novel coronavirus. Shares in BrightGene tanked after…
Boehringer bags CHMP backing for Ofev in rare lung disease
Boehringer Ingelheim has moved a step closer to getting approval for its blockbuster respiratory drug Ofev as the first treatment in the EU for a rare, life-threatening fibrotic disease. The EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended…
